Apellis Pharmaceuticals (APLS) Competitors

Apellis Pharmaceuticals logo
$28.11 +0.71 (+2.59%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

APLS vs. ITCI, VTRS, GMAB, MRNA, RDY, SRPT, PCVX, QGEN, ROIV, and ASND

Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

Apellis Pharmaceuticals vs.

Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.

Intra-Cellular Therapies received 177 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 67.25% of users gave Apellis Pharmaceuticals an outperform vote while only 67.01% of users gave Intra-Cellular Therapies an outperform vote.

CompanyUnderperformOutperform
Apellis PharmaceuticalsOutperform Votes
345
67.25%
Underperform Votes
168
32.75%
Intra-Cellular TherapiesOutperform Votes
522
67.01%
Underperform Votes
257
32.99%

In the previous week, Apellis Pharmaceuticals had 9 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 18 mentions for Apellis Pharmaceuticals and 9 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.66 beat Apellis Pharmaceuticals' score of 0.36 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apellis Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intra-Cellular Therapies
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Intra-Cellular Therapies has higher revenue and earnings than Apellis Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis Pharmaceuticals$396.59M8.59-$528.63M-$2.03-13.50
Intra-Cellular Therapies$464.37M29.27-$139.67M-$0.87-146.92

Apellis Pharmaceuticals currently has a consensus target price of $46.71, indicating a potential upside of 70.46%. Intra-Cellular Therapies has a consensus target price of $103.62, indicating a potential downside of 18.94%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Apellis Pharmaceuticals is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apellis Pharmaceuticals
0 Sell rating(s)
8 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.63
Intra-Cellular Therapies
0 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.53

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Intra-Cellular Therapies has a net margin of -14.07% compared to Apellis Pharmaceuticals' net margin of -34.97%. Intra-Cellular Therapies' return on equity of -9.93% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals-34.97% -103.11% -28.96%
Intra-Cellular Therapies -14.07%-9.93%-8.38%

Apellis Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Apellis Pharmaceuticals and Intra-Cellular Therapies tied by winning 9 of the 18 factors compared between the two stocks.

Get Apellis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLS vs. The Competition

MetricApellis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.41B$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio-13.509.7126.2919.46
Price / Sales8.59290.45455.7377.34
Price / CashN/A75.4646.0638.90
Price / Book16.715.537.325.05
Net Income-$528.63M$123.46M$3.19B$222.81M
7 Day Performance-3.96%3.13%2.64%1.94%
1 Month Performance-8.45%2.14%4.00%1.48%
1 Year Performance-60.16%1.28%21.96%16.47%

Apellis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLS
Apellis Pharmaceuticals
4.3656 of 5 stars
$28.11
+2.6%
$46.71
+66.2%
-60.2%$3.51B$396.59M-13.89770Short Interest ↓
ITCI
Intra-Cellular Therapies
4.1283 of 5 stars
$127.12
+0.1%
$103.62
-18.5%
+69.0%$13.52B$612.78M-146.11560Analyst Forecast
Short Interest ↑
VTRS
Viatris
3.3864 of 5 stars
$10.62
-1.1%
$13.67
+28.7%
-17.3%$12.67B$15.43B-14.3438,000
GMAB
Genmab A/S
4.8409 of 5 stars
$18.69
-1.7%
$45.20
+141.9%
-25.8%$12.37B$2.39B18.142,204Earnings Report
Short Interest ↓
Analyst Revision
News Coverage
MRNA
Moderna
4.8375 of 5 stars
$31.87
-2.2%
$67.26
+111.1%
-62.7%$12.26B$6.85B-5.485,600Analyst Downgrade
RDY
Dr. Reddy's Laboratories
2.9912 of 5 stars
$13.83
-0.5%
$17.00
+23.0%
-9.9%$11.54B$3.35B22.0127,048
SRPT
Sarepta Therapeutics
4.5456 of 5 stars
$112.68
+0.8%
$178.71
+58.6%
-19.8%$10.76B$1.24B90.151,314Gap Down
PCVX
Vaxcyte
2.6765 of 5 stars
$85.94
-1.7%
$145.71
+69.6%
+11.6%$10.71BN/A-18.68160
QGEN
Qiagen
4.1141 of 5 stars
$40.10
-3.0%
$48.78
+21.6%
-4.8%$8.90B$1.98B111.665,967
ROIV
Roivant Sciences
3.6177 of 5 stars
$10.77
-1.1%
$17.93
+66.5%
-8.9%$7.84B$124.79M1.91860
ASND
Ascendis Pharma A/S
3.2928 of 5 stars
$119.47
-1.2%
$191.57
+60.3%
-7.9%$7.25B$288.08M-14.79640Earnings Report
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:APLS) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners